Patent application number | Description | Published |
20120208819 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS - The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases. | 08-16-2012 |
20140371209 | S1P Modulating Agents - Compounds of formula (I) or (II) can modulate the activity of SIP receptors. | 12-18-2014 |
20150183741 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS - Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). | 07-02-2015 |
20150203493 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS - Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). | 07-23-2015 |
20150203515 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS - Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). | 07-23-2015 |
20150210647 | ATX MODULATING AGENTS - Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer. | 07-30-2015 |
20150232492 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 08-20-2015 |
20150246063 | ATX MODULATING AGENTS - Compounds of formula (I) can modulate the activity of autotaxin (ATX). | 09-03-2015 |
Patent application number | Description | Published |
20080234271 | Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them - The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject. | 09-25-2008 |
20100035918 | Imidazolone Compounds and Methods of Making and Using the Same - In one aspect, the invention features a compound of the general Formula (I). Compounds of Formula (I) possess high affinity for Alk 5 and/or AIk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. | 02-11-2010 |
20100056505 | Substituted Pyrazalones - The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable. | 03-04-2010 |
20100144730 | PYRIDINONYL PDK1 INHIBITORS - The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same. | 06-10-2010 |
20100240617 | BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 09-23-2010 |
20110152260 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase - The present invention relates to modulators of IRAK kinases of formula (I) and provides compositions comprising such modulators, as well as methods therewith for treating IRAK-mediated or IRAK-associated conditions or diseases. | 06-23-2011 |
20150018351 | PYRIDINONYL PDK1 INHIBITORS - The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same. | 01-15-2015 |
Patent application number | Description | Published |
20100160258 | Bicyclic aryl sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 06-24-2010 |
20100160357 | Heterobicyclic sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 06-24-2010 |
20130059821 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors. | 03-07-2013 |
20140100195 | Heterobicyclic sphingosine 1-phosphate analogs - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 04-10-2014 |
Patent application number | Description | Published |
20120021707 | APPARATUS AND METHOD FOR ADJUSTMENT OF TRANSMITTER POWER IN A SYSTEM - Certain aspects of the present disclosure propose methods for determining power level of one or more transmitters based on a power level of a primary transmitter when the transmitters are located in close proximity of each other. The power levels may be determined such that a combined power of all the transmitters is compliant with regulatory radio frequency (RF) safety requirements. For certain aspects, power level of the lower priority transmitters may be determined utilizing one or more look-up tables. For another aspect, power level of the lower priority transmitters may be calculated using an algorithm based on the power level of the priority transmitter. In aspects, the power level of lower priority transmitters and the time duration for which the transmitters are active may be selected dynamically so that the time averaged power of the transmitters for a defined period of time falls below the RF exposure limit. | 01-26-2012 |
20140273819 | NEAR-FIELD EQUIVALENT SOURCE REPRESENTATION FOR SAR ESTIMATION - Efficient techniques for estimating specific absorption rate (SAR) for wireless devices. In an aspect, electric and/or magnetic field measurements are made over a two-dimensional (2D) surface in the proximity of a wireless device. The field measurements are used to generate a near-field equivalent source representation of the wireless device. Specific absorption rate over, e.g., a 1 g/10 g mass may then be calculated by performing electromagnetic simulations using the near-field equivalent source representation. In an aspect, an elementary dipole array may be used to generate the near-field equivalent source representation from the field measurements. | 09-18-2014 |
20140274190 | REAL-TIME EXPOSURE ASSESSMENT - Efficient techniques for determining compliance of a wireless device with radio-frequency (RF) exposure standards and regulations. In an aspect, two-dimensional surface scans of a device are determined and stored in a memory during a certification phase. Each scan corresponds to a basis surface scan wherein only one transmitter and one antenna of the device are active. During real-time operation, the basis surface scans corresponding to the real-time active transmitters and antennas of the device are retrieved. The retrieved scans are processed according to the real-time operating parameters to determine an estimated RF exposure metric, e.g., a peak specific absorption rate (SAR). The transmit power levels of the device may be adjusted in real time to ensure compliance of the estimated RF exposure metric with applicable standards and regulations. | 09-18-2014 |
20150177302 | COMPLIANCE ASSESSMENT OF HUMAN EXPOSURE FROM WIRELESS ELECTRIC VEHICLE CHARGING SYSTEM - This disclosure provides systems, methods and apparatus for assessing electromagnetic exposure. In one aspect an apparatus is provided. The apparatus includes at least a first circuit configured to calculate electromagnetic exposure of at least a portion of at least one human in proximity to a wireless electric vehicle charging system. The portion of the at least one human is modeled by at least one homogeneous phantom model having dielectric properties that are representative of human tissue. The apparatus further includes at least a second circuit configured to scale the calculated electromagnetic exposure to simulate an electromagnetic exposure based on an inhomogeneous anatomical model of the portion of the at least one human. | 06-25-2015 |
20150197155 | CONTROLLING CURRENT FLOW PATH IN WIRELESS ELECTRIC VEHICLE CHARGING SYSTEMS FOR MITIGATING RF RADIATED EMISSIONS - This disclosure provides systems, methods and apparatus for mitigating electromagnetic radiation emissions. In one aspect, a power transfer device of a wireless electric vehicle charging (WEVC) system is provided. The power transfer device includes a ferrite material and at least one electrically conductive coil. The ferrite material and the at least one coil are configured to wirelessly transfer energy either from or to a second power transfer device of the WEVC system. The power transfer device further includes at least one shield comprising a plurality of electrically conducting regions and one or more electrically insulating regions. The plurality of electrically conducting regions and one or more electrically insulating regions are configured to mitigate electromagnetic radiation emissions from the WEVC system that do not contribute to the wireless power transfer between the at least one electrically conductive coil and the second power transfer device. | 07-16-2015 |